Scott Dell

Eli Lilly and Company

Scott Dell is currently Vice President, US Value Evidence and Outcomes (VEO), at Eli Lilly and Company. Scott joined Lilly in June 2002 after earning his MBA in marketing and strategy from the IU Kelley Graduate School of Business. During his first 20 years with the company, Scott held leadership roles of increasing responsibility in Lilly’s US commercial business, including brand market access, government strategy, professional relations, payer contract development and analytics, and new product planning. Scott also led the regional managed markets account organization which was responsible for managing relationships with regional payers and health systems (Medicaid, Part D, Managed Care) across the US. Scott also spent two years in corporate strategy where he led enterprise-wide projects sponsored by Lilly’s executive committee, which included developing the company’s long-term growth strategy.

Scott assumed his current role in June 2022 and in this capacity leads an external US customer engagement team responsible for delivering clinical, budget impact, and real-world evidence supporting Lilly’s portfolio to US population-based decision makers. His team is also accountable for facilitating research collaborations with US payers and health systems, value-based agreement concept development and evaluation, and ensuring US population-based customer insights are integrated into real world evidence studies for Lilly’s key therapeutic areas of focus: Oncology, Diabetes and Obesity, Immunology, and Neuroscience.

Prior to Lilly, Scott worked in consulting services for Deloite and Ernst & Young and led enterprise-wide SAP information technology projects, including several implementations in the healthcare segment. Scott graduated cum laude with a Bachelor of Science degree in accounting and information technology.